ABVC BioPharma, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-05$2.35 RISE2026-05-11$1.02 PEAK2026-05-28$1.41 143d | -56.6% 126d | Missed | Missed | — | — | +38.2% 17d | Missed |
DROP2025-11-18$2.92 RISE2026-03-30$0.91 PEAK2026-04-07$1.45 140d | -68.9% 132d | Missed | Missed | — | — | +59.5% 8d | Missed |
DROP2025-08-15$3.30 RISE2025-12-15$2.03 PEAK2025-12-26$2.43 133d | -38.5% 122d | Missed | Missed | — | — | +19.7% 11d | Missed |
DROP2025-07-08$4.74 RISE2025-07-31$2.40 PEAK2025-08-15$3.30 38d | -49.4% 23d | Missed | Missed | — | — | +37.5% 15d | Missed |
DROP2024-10-28$0.74 RISE2025-02-13$0.42 PEAK2025-05-12$1.36 196d | -43.4% 108d | Missed | Missed | — | — | +224.6% 88d | Missed |
DROP2024-08-14$0.75 RISE2024-12-10$0.48 PEAK2025-02-26$0.81 196d | -36.7% 118d | Missed | Missed | — | — | +71.2% 78d | Missed |
DROP2024-07-17$0.93 RISE2024-10-11$0.47 PEAK2024-10-28$0.74 103d | -49.2% 86d | Missed | Missed | — | — | +56.8% 17d | Missed |
DROP2024-04-25$1.59 RISE2024-06-21$0.71 PEAK2024-07-17$0.93 83d | -55.2% 57d | Missed | Missed | — | — | +30.4% 26d | Missed |
DROP2024-01-03$1.93 RISE2024-04-19$0.99 PEAK2024-04-25$1.59 113d | -48.7% 107d | Missed | Missed | — | — | +60.6% 6d | Missed |
DROP2023-08-04$2.74 RISE2023-12-12$1.05 PEAK2024-01-03$1.93 152d | -61.7% 130d | Missed | Missed | — | — | +83.8% 22d | Missed |
DROP2023-08-03$3.08 RISE2023-12-11$1.05 PEAK2024-01-03$1.93 153d | -65.9% 130d | Missed | Missed | — | — | +83.8% 23d | Missed |
DROP2023-05-30$6.81 RISE2023-10-06$0.81 PEAK2023-11-24$2.02 178d | -88.1% 129d | Missed | Missed | — | — | +149.4% 49d | Missed |
DROP2023-01-05$10.70 RISE2023-03-16$5.70 PEAK2023-05-09$9.20 124d | -46.7% 70d | Missed | Missed | — | — | +61.4% 54d | Missed |
DROP2022-09-08$11.40 RISE2023-01-03$6.00 PEAK2023-01-05$10.70 119d | -47.4% 117d | Missed | Missed | — | — | +78.3% 2d | Missed |
DROP2022-09-08$11.40 RISE2022-10-24$6.70 PEAK2023-01-05$10.70 119d | -41.2% 46d | Missed | Missed | — | — | +59.7% 73d | Missed |
1–15 / 27 1 / 2 | |||||||
No scored news yet for a sentiment trend.
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.06) per share. This is unchanged from the same period last year.
SILO stock rose 51.8% in pre-market trading after its PTSD treatment pipeline received a patent from the European Patent Office targeting 5-HT4.
Total Assets Increase 179% to $21.06 Million as Company Strengthens Asset-Backed Licensing Model SILICON VALLEY, CA - March 3, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced the filing of its Annual Report on Form 10-K for...
- SEC Filing
SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingredient platforms, today pr...
SILICON VALLEY, CA - December 2, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today addressed recent public discussions surrounding attention-deficit/hyperactivity disorder (ADHD) treatment in the United States[...
SILICON VALLEY, CA - November 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today announced that its wholly owned subsidiary, BioKey (Cayman), Inc. ("BioKey"), has strengthened its operational platform and lo...
SILICON VALLEY, CA - November 21, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) announced today that ForSeeCon Eye Corporation ("ForSeeCon") has made an additional US$250,000 payment under the existing ophthalmic...
SILICON VALLEY, CA - November 18, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received an additional US$240,000 licensing payment from its partner OncoX BioPharma, Inc. ("OncoX") un...
SILICON VALLEY, CA - November 3, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc.. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indicatio...
ABVC BioPharma (NASDAQ:ABVC) reported quarterly losses of $(0.05) per share. This is a 66.67 percent decrease over losses of $(0.03) per share from the same period last year. The company reported $795.950 thousand in
OncoX's "Technology Performance Asset" Business Model Drives ABVC's Licensing Portfolio Revaluation SILICON VALLEY, CA - October 31, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced that its oncology partner OncoX BioPharma...
SILICON VALLEY, CA - October 17, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (C...
SILICON VALLEY, CA - October 8, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received a US$70,000 licensing payment from its partner, ForSeeCon Eye Corporation ("ForSeeCon"), under th...
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. ABVC BioPharma, Inc. is one of them. ABVC BioPharma, Inc. (NASDAQ:ABVC) tops our list for being one of the best penny stocks. It is a clinical-stage biopharmaceutical company developing botanically derived therapeutics for oncology, neurology, […]
In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. ABVC BioPharma, Inc. is one of them. ABVC BioPharma, Inc. (NASDAQ:ABVC) tops our list for being one of the best penny stocks. It is a clinical-stage biopharmaceutical company developing botanically derived therapeutics for oncology, neurology, […]
SILICON VALLEY, CA - September 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc.. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received a licensing payment of US$145,950 from OncoX BioPharma, Inc. ("OncoX") under the terms of the...
SILICON VALLEY, CA - August 29, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CN...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABVC | +36.89% | -4.73% | -33.80% | +2.92% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +33.92% | +0.99% | -30.36% | -9.77% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 95.1K | $92.26K | 0.00% | Trimmed-16.8% | 2026-03-31 |
| StateStreet | passive | 72.8K | $70.62K | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-05-15 | -0.50 | -0.60 | -20.00% |
| 2023-03-31 | -1.50 | -1.50 | — |
| 2022-11-14 | -2.00 | -1.10 | +45.00% |
| 2022-08-15 | -1.25 | -0.60 | +52.00% |
| 2022-03-31 | -0.40 | -3.10 | -675.00% |
| 2021-11-15 | -0.40 | -0.70 | -75.00% |
| 2021-08-12 | -0.40 | -0.80 | -100.00% |
| 2021-03-16 | -1.00 | -2.43 | -142.96% |